文献速递间质性肺疾病

体表面积调整吡非尼酮剂量在间质性肺炎中的分析

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.
PubMed 文献 · Respirology · 2017-08-29

该回顾性研究纳入67例日本间质性肺炎患者(其中46例为IPF),评估按体表面积(BSA)或体重调整吡非尼酮剂量对预防不良事件(AE)和维持治疗的作用。结果显示AE组BSA和体重调整剂量均显著更高,BSA调整剂量可区分AE患者(AUC=0.666 at 1085 mg/m2),且IPF亚组中中等剂量者%FVC年下降更少。

要点

  • BSA调整的吡非尼酮剂量与AE发生显著相关,较高调整剂量者AE风险增加。
  • 因AE停药的患者中85.7%接受≥1085 mg/m2的BSA调整剂量。
  • IPF亚组中中等BSA调整剂量(876-1085 mg/m2)者%FVC年下降低于低剂量者。

核心结论

  • BSA调整的吡非尼酮剂量可能有助于预防AE并实现长期治疗效果。

研究设计与样本

  • 回顾性研究,纳入2009至2015年间67例日本间质性肺炎患者,其中46例为IPF,均接受吡非尼酮治疗。

主要发现

  • AE组BSA调整剂量和体重调整剂量均显著高于无AE组(P=0.024和P=0.010),未调整剂量无差异。
  • BSA调整剂量区分AE的AUC为0.666(截点1085 mg/m2)。
  • 因AE停药的7例中6例(85.7%)接受≥1085 mg/m2的BSA调整剂量。
  • IPF亚组中中等剂量(中位数876至1085 mg/m2)者%FVC年下降低于低剂量者(P=0.025)。

关键数值与推荐

  • BSA调整剂量截点1085 mg/m2对应AUC=0.666。
  • IPF亚组中等剂量范围为876至1085 mg/m2。

临床怎么用

  • 临床可考虑按BSA调整吡非尼酮剂量以平衡疗效与AE风险。

局限性

  • 回顾性设计,样本量较小(67例),仅日本人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pirfenidone is an effective anti-fibrotic agent for idiopathic pulmonary fibrosis (IPF). Although adverse events (AE) sometimes prevent patients from continuing treatment, current dose adjustment guidance does not consider patient body size or weight (BW). The aim of this study was to evaluate the importance of pirfenidone dose adjustment by body surface area (BSA) or BW for preventing AE and permitting continuous treatment in patients with interstitial pneumonia (IP). METHODS: Sixty-seven Japanese patients with IP including 46 patients with IPF treated with pirfenidone between 2009 and 2015 were retrospectively evaluated. Pirfenidone doses were adjusted by BSA or BW and were compared with clinical parameters. RESULTS: Forty-two of 67 patients (62.7%) with IP showed AE, most commonly gastrointestinal symptoms (77.5%). Patients having AE received significantly higher adjusted doses of pirfenidone by both BSA and BW (P = 0.024 and P = 0.010, respectively), while unadjusted doses did not differ. BSA-adjusted dose discriminated patients with AE from those without (area under the curve = 0.666 at 1085 mg/m2 ). Six of seven patients (85.7%) who discontinued pirfenidone due to AE took ≥1085 mg/m2 of pirfenidone. In a subgroup with IPF, patients taking a medium dose (median: 876 median-1085 mg/m2 ) showed a lower annual decline in % forced vital capacity than patients taking a lower dose (P = 0.025). CONCLUSION: BSA-adjusted pirfenidone dosing may be useful to prevent AE whilst achieving a long-term treatment effect in patients with IP.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Uehara M, Enomoto N, Oyama Y, et al. Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology. 2017. PMID: 28851013. doi:10.1111/resp.13145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。